Product Name: LFNG antibody, N-term
Applications: WB
Predicted Target Size: 42 KDa (note)
Positive Controls: human fetal muscle
Form Supplied: Liquid
Concentration: 0.5-1 mg/ml
Purification: Affinity Purified
Full Name: LFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase
Background: This gene is a member of the fringe gene family which also includes radical and manic fringe genes. They all encode evolutionarily conserved glycosyltransferases that act in the Notch signaling pathway to define boundaries during embryonic development. While their genomic structure is distinct from other glycosyltransferases, fringe proteins have a fucose-specific beta-1,3-N-acetylglucosaminyltransferase activity that leads to elongation of O-linked fucose residues on Notch, which alters Notch signaling. This gene product is predicted to be a single-pass type II Golgi membrane protein but it may also be secreted and proteolytically processed like the related proteins in mouse and Drosophila (PMID: 9187150). Mutations in this gene have been associated with autosomal recessive spondylocostal dysostosis 3. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Oct 2009]
Synonyms: LFNG Antibody , SCDO3 Antibody
Cellular Localization:
CAS NO: 193746-75-7
Product: Trenbolone (acetate)
Host: Rabbit
Clonality: Polyclonal
Isotype: IgG
Immunogen: A synthetic peptide corresponding to a N-terminal region of Human LFNG
Antigen Species: Human
Species Reactivity: Human
Conjugation: Unconjugated
Storage Buffer: 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose.
Storage Instruction: Keep as concentrated solution. For short-term storage, store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
Notes: For In vitro laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Specificity:
PubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/21296869?dopt=Abstract
